Related Experiment Video

Updated: Dec 7, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis

Kanila Perera1, Ning Kam1, Zanfina Ademi1

  • 1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Journal of Clinical Lipidology
|September 30, 2020
PubMed

Insights

Bempedoic acid, a novel cholesterol-lowering drug, is cost-effective for high cardiovascular disease risk patients in Australia. At an annual cost under $600, it offers significant health gains, saving lives and improving quality of life.

Area of Science:

  • Cardiovascular Disease Research
  • Health Economics
  • Pharmacoeconomics

Background:

  • Bempedoic acid is a new adenosine triphosphate citrate lyase inhibitor.
  • It effectively lowers low-density lipoprotein cholesterol.
  • It is used as an additional therapy for patients at high risk of cardiovascular disease (CVD).

Purpose of the Study:

  • To determine the cost-effectiveness of bempedoic acid in Australia.
  • To identify the price threshold for bempedoic acid to be considered cost-effective.

Main Methods:

  • A Markov model was developed using data from the CLEAR Harmony trial.
  • The model simulated clinical outcomes and costs for 1000 patients over a lifetime.
  • Cost-effectiveness was assessed using incremental cost-effectiveness ratios (ICERs) per QALY gained and per year of life saved, with a 5% discount rate.

Main Results:

  • Bempedoic acid, combined with statin therapy, was projected to save 122 discounted life-years and 103 discounted quality-adjusted life-years (QALYs) per 1000 individuals.
  • At an annual acquisition cost of AU$584.40, the ICER was AU$49,890 per QALY gained and AU$42,433 per year of life saved.
  • These results suggest cost-effectiveness within the Australian healthcare system.

Conclusions:

  • Bempedoic acid demonstrates cost-effectiveness in the Australian healthcare context.
  • An annual acquisition price below AU$600 is likely to render bempedoic acid cost-effective.
  • This finding supports the use of bempedoic acid as a valuable addition to lipid-lowering therapies.
Abstract

Keywords:
Bempedoic acidCardiovascular diseaseCost-effectivenessLipid-loweringPrevention

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.0K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
223
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.0K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
293
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
612